Australia’s active vaccine safety system


Tran H, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan C, Gold M, Hissaria P, Melody S, Chunilal S, Buttery J, Clothier H, Crawford N, Phuong L, Pepperell D, Effler P, Parker C, Carter N. The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study. The Lancet Western Pacific. doi:10.1016/j.lanwpc.2023.100894. [Full text]

Deng L, Lopez L, Glover C, Cashman P, Reynolds R, Macartney K, Wood N. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox. JAMA. 2023;329(23):2091-2094. doi:10.1001/jama.2023.7683. [Full text]

Deng L, Glover C, Dymock M, Pillsbury A, Marsh JA, Quinn HE, Leeb A, Cashman P, Snelling TL, Wood N, Macartney K. The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Medical Journal of Australia. doi: 10.5694/mja2.51619. [Full text]

Phillips A, Glover C, Leeb A, Cashman P, Fathima P, Crawford C, Snelling TL, Durrheim D, Macartney K. Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance. BMJ Open. 2021;11:e043880 . [Abstract]

Totterdell J, Phillips A, Glover C, Chidwick K, Marsh J, Snelling T, Macartney K. Safety of live attenuated herpes zoster vaccine in adults 70 to 79 years: a self-controlled case series analysis using primary care data from the MedicineInsight program. Vaccine. 2020;38:3968-3979. [Abstract]

Glover C, Crawford N, Leeb A, Wood N, Macartney K. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety. Vaccine. 2020;38:4892-4900. [Abstract]

Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney K . Comparative post-market safety profile of adjuvanted and high-dose influenza vaccines in the elderly. JAMA Open. 2020;3(5):e204079 . [Full text]

Jacoby P, Glover C, Damon C, Fathima P, Pillsbury A, Durrheim D, Gold M, Leeb A, Snelling T. Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study. BMJ Open 2020;10:e031851 . [Full text]

P. Cashman, S. Moberley, K. Chee, J. Stephenson, S. Chaverot, J. Martinelli, T. Gadsden, C. Bateman-Steel, L. Redwood, Z. Howard, M.J. Ferson and D.N. Durrheim. Participant centred safety surveillance of health care workers receiving influenza vaccination. Vaccine 2019;37:2427-2429. [Abstract]

Crawford NW, Hodgson K, Gold M, Buttery J, Wood N. Adverse evens following HPV immunisation in Australia: establishment of a clinical network. Human Vaccines and Immunotherapeutics 2016;12:2662-5. [Full text]